Study of the Effect of N-acetylcysteine on Urinary Tract Infection in Children.

Study of the Effect of N-acetylcysteine Compared with Placebo on Inflammation Biomarkers of Acute Pyelonephritis in Children.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013112015465N1

Enrollment

Registered

2014-01-21

Start date

2014-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pyelonephritis. Acute tubulo-interstitial nephritis

Interventions

Intervention 1: Effervescent tablet of N-acethyl cystein 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 k

Treatment - Drugs

Effervescent tablet of N-acethyl cystein 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg

Placebo effervescent tablet of N-acethyl cystein 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily: more than 30 kg: 1.

Eligibility

Sex/Gender

All

Age

1 Years to 16 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients between the ages of 1 and 16; Having the diagnosis of "definite" or "probable" urinary tract infection according to guidelines of "pediatric infectious disease research center". Exclusion criteria: Patients younger than 1 or older than 16 years old; Patients without the diagnosis of "definite" or "probable" urinary tract infection according to guidelines of "pediatric infectious disease research center"; Patients with acute/ chronic infectious or inflammatory diseases other than pyelonephritis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum procalcitonin. Timepoint: Before giving drug, and 5 days after giving the drug. Method of measurement: Serum procalcitonin test.;CRP. Timepoint: Before and 5 days after starting therapy. Method of measurement: Blood test.;Leukocyte count. Timepoint: Before and 5 days after starting therapy. Method of measurement: Blood test.	—

Secondary

Measure	Time frame
Probable adverse effects (nausea, vomiting, bad tasting, stomatitis, ...). Timepoint: Daily. Method of measurement: Clinical examination and asking from patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Allameh

Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.

Zahra_allameh@yahoo.comzahraallameh@gmail.com+98 31 1273 6097

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026